



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/756,097	01/08/2001	Lloyd G. Mitchell	A31304-B-A-C	5648
38485 7	7590 03/10/2006		EXAMINER	
ARENT FOX PLLC			ZARA, JANE J	
1675 BROADWAY NEW YORK, NY 10019			ART UNIT	PAPER NUMBER
			1635	757
			DATE MAILED: 03/10/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	09/756,097	MITCHELL ET AL.					
Office Action Summary	Examiner	Art Unit					
	Jane Zara	1635					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1) Responsive to communication(s) filed on 15 F	ebruary 2002.						
, <u> </u>	action is non-final.						
,—	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>1-28</u> is/are pending in the application.							
, , ,	4a) Of the above claim(s) (1/2) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.	• • ——						
8) Claim(s) 1-28 are subject to restriction and/o	or election requirement.						
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
 Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No 							
						3. Copies of the certified copies of the priority documents have been received in this National Stage	
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)	_						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date							
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) 		ratent Application (PTO-152)					
Paper No(s)/Mail Date 6) Other:							

Application/Control Number: 09/756,097

Art Unit: 1635

DETAILED ACTION

Claims 1-28 are pending in the instant application.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- 1. Claims 1, 3-5, 7-9, 11-13, 15-19, 21-24, 26 and 27, drawn to compositions and methods comprising trans-spicing via a 3' splice region comprising a 3' splice acceptor site, classified in class 435, subclass 6.
- II. Claims 2, 6, 10, 14, 20, 23, 25, 27 and 28, drawn to compositions and methods comprising trans-spicing via a 5' splice region comprising a 5' splice acceptor site, classified in class 435, subclass 6.

The inventions are distinct, each from the other because of the following reasons: Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the nucleic acids and methods comprising them are biologically, structurally and functionally different and distinct from each other. The methods involving trans-splicing using a nucleic acid construct comprising a 3' splice region comprising a 3' splice acceptor site utilizes different and distinct compositions and distinct methods steps from the method involving a 5' splice region comprising a 5'

splice acceptor site. For these reasons, the inventions of Groups I and II are patentably distinct.

Furthermore, searching the inventions of Groups I and II together would impose a serious search burden. In the instant case, the search of the two distinct methods and compositions are not coextensive. These is a search burden also in the non-patent literature. Prior to the concomitant construction and utilization of the different nucleic acid construct of interest there may be journal articles devoted solely to one Groups that would not have described the compositions and methods of the other Group.

Searching, therefore is not coextensive. As such, it would be burdensome to search the inventions of Groups I and II together.

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the method of trans splicing using a construct comprising a 3' splice region comprising a 3' splice acceptor site of Group I, and the trans splicing method using a 5' splice region comprising a 5' splice acceptor site of Group II are unrelated as they comprise distinct steps and utilize different nucleic acid constructs which demonstrates that each method has a different mode of operation. The methodology and materials necessary for each of these distinct methods differ significantly, and each Group constitutes a biologically, chemically and functionally distinct and different composition and method and therefore each involves a patentably distinct invention.

Application/Control Number: 09/756,097

Art Unit: 1635

Therefore, each method is divergent in materials and steps. For these reasons the inventions of Groups I and II are patentably distinct.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. 1.6(d)). The official fax telephone number for the Group is **571-273-8300**. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO

Application/Control Number: 09/756,097 Page 5

Art Unit: 1635

DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jane Zara** whose telephone number is **(571) 272-0765**. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang, can be reached on (571) 272-0811. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (571) 272-0564. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jane Zara 3-6-06

> JANE ZARA, PH.D. PRIMARY EXAMINER